{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:42:50Z","timestamp":1787877770702,"version":"build-2784847793"},"reference-count":97,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The pathologic triangle formed by chronic heart failure (HF), chronic kidney disease (CKD), and anemia carries high morbidity and mortality rates and decreases quality of life. Anemia represents a common condition in patients with advanced HF and CKD, with a total prevalence in cardiorenal syndrome (CRS) ranging from 5% to 55%. Searching for a pragmatic approach for these patients with guided and disease-specific recommendations beyond just targeted hemoglobin therapeutic behavior represents the core of research for ongoing clinical trials. It is well known that the prevalence of anemia increases with the advancement of CKD and HF. The physiopathological mechanisms of anemia, such as the reduction of endogenous erythropoietin and the decrease in oxygen transport, are leading to tissue hypoxia, peripheral vasodilation, stimulating neurohormonal activity, and maintenance of the progressive renal and cardiac dysfunction. Given the challenges with the treatment options for patients with cardiorenal anemia syndrome (CRSA), new therapeutic agents such as hypoxia-inducible factor\u2013prolyl hydroxylase domain inhibitors (HIF-PH) or hepcidin antagonists are emerging in the light of recent research. This review summarizes the potential therapeutic tools for anemia therapy in the cardiorenal population.<\/jats:p>","DOI":"10.3390\/life13061311","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T01:33:54Z","timestamp":1685669634000},"page":"1311","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Managing Anemia: Point of Convergence for Heart Failure and Chronic Kidney Disease?"],"prefix":"10.3390","volume":"13","author":[{"given":"Oana Nicoleta","family":"Buliga-Finis","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Internal Medicine Clinic, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Ouatu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Internal Medicine Clinic, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7144-2506","authenticated-orcid":false,"given":"Daniela Maria","family":"Tanase","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Internal Medicine Clinic, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-9306","authenticated-orcid":false,"given":"Evelina Maria","family":"Gosav","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Internal Medicine Clinic, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronela Nicoleta","family":"Seritean Isac","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Internal Medicine Clinic, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Richter","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Physiotherapy, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Rheumatology Clinic, Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Internal Medicine Clinic, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000313718","article-title":"Cardiorenal syndromes: Definition and classification","volume":"164","author":"Ronco","year":"2010","journal-title":"Contrib. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"837270","DOI":"10.3389\/fcvm.2022.837270","article-title":"Mitochondrial Dysfunction: An Emerging Link in the Pathophysiology of Cardiorenal Syndrome","volume":"9","author":"Shi","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.33393\/gcnd.2017.674","article-title":"The Cardiorenal Anemia Syndrome. Part One: Epidemiology and Clinical Aspects","volume":"29","author":"Rivera","year":"2017","journal-title":"G. Tec. Nefrol. Dial."},{"key":"ref_5","first-page":"9","article-title":"Cardiorenal-anemia syndrome\u2014Definition, epidemiology and management: The Cardiologist\u2019s view","volume":"15","author":"Farmakis","year":"2011","journal-title":"Hippokratia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1017\/S1368980008002401","article-title":"Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993\u20132005","volume":"12","author":"McLean","year":"2009","journal-title":"Public Health Nutr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.ekir.2021.05.020","article-title":"Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease","volume":"6","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ccl.2019.04.001","article-title":"Cardiorenal Syndrome: Pathophysiology","volume":"37","author":"Kumar","year":"2019","journal-title":"Cardiol. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.kisu.2020.12.001","article-title":"Anemia of cardiorenal syndrome","volume":"11","author":"McCullough","year":"2021","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents","volume":"8","author":"Broseta","year":"2021","journal-title":"Front. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in Patients with Anemia and Non\u2013Dialysis-Dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","unstructured":"KDIGO Anemia Working Group (2012). KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int., 2, 279\u2013335."},{"key":"ref_14","first-page":"108","article-title":"Hepcidin in chronic kidney disease: Not an anaemia management tool, but promising as a cardiovascular biomarker","volume":"73","author":"Grooteman","year":"2015","journal-title":"Neth. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000081058","article-title":"Anemia and diabetes","volume":"24","author":"Deray","year":"2004","journal-title":"Am. J. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1634\/theoncologist.2009-S1-22","article-title":"Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syn-drome","volume":"14","author":"Besarab","year":"2009","journal-title":"Oncologist"},{"key":"ref_17","first-page":"236","article-title":"Anemia and cardiorenal syndrome in heart failure: Review article","volume":"17","author":"Marecos","year":"2010","journal-title":"Med. Interna"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s41100-020-00311-x","article-title":"A new insight into the treatment of renal anemia with HIF stabilizer","volume":"6","author":"Kuriyama","year":"2020","journal-title":"Ren. Replace Therapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"365301","DOI":"10.4061\/2011\/365301","article-title":"Correction of Iron Deficiency in the Cardiorenal Syndrome","volume":"2011","author":"Silverberg","year":"2011","journal-title":"Int. J. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.nefro.2020.07.009","article-title":"Intravenous iron in heart failure and chronic kidney disease","volume":"41","author":"Carrilho","year":"2021","journal-title":"Nefrologia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e0151601","DOI":"10.1371\/journal.pone.0151601","article-title":"Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2018.07.003","article-title":"Erythropoietic regulators of iron metabolism","volume":"133","author":"Ganz","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2008.10.046","article-title":"Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure?","volume":"53","author":"Kazory","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-Inducible Factors in Physiology and Medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1157\/13108999","article-title":"Anemia in heart failure: Pathophysiology, pathogenesis, treatment, and incognitae","volume":"60","author":"Caramelo","year":"2007","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/28867","article-title":"Role of HIF-1 in hypoxia- mediated apoptosis, cell proliferation and Tumor angiogenesis","volume":"394","author":"Carmeliet","year":"1998","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jacbts.2020.05.006","article-title":"Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders","volume":"5","author":"Packer","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2169\/internalmedicine.43.649","article-title":"Molecular Biology of Erythropoietin","volume":"43","author":"Jelkmann","year":"2004","journal-title":"Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ndt\/16.suppl_7.2","article-title":"Anaemia in end-stage renal disease: Pathophysiological considerations","volume":"16","author":"Eckardt","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1056\/NEJMra1612008","article-title":"Physiological effects of chronic hypoxia","volume":"376","author":"West","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.kint.2019.10.007","article-title":"The noblesse of kidney physiology","volume":"96","author":"Eckardt","year":"2019","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"837249","DOI":"10.3389\/fphar.2022.837249","article-title":"Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases","volume":"13","author":"Miao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103942","DOI":"10.1016\/j.ebiom.2022.103942","article-title":"Hypoxia and chronic kidney disease","volume":"77","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Singer, C.E., Vasile, C.M., Popescu, M., Popescu, A.I.S., Marginean, I.C., Iacob, G.A., Popescu, M.D., and Marginean, C.M. (2023). Role of Iron Defificiency in Heart Failure\u2014Clinical and Treatment Approach: An Overview. Diagnostics, 13.","DOI":"10.3390\/diagnostics13020304"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.34067\/KID.0001442020","article-title":"Management of Anemia in Nondialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives","volume":"1","author":"Guedes","year":"2020","journal-title":"Kidney360"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and non-anemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1111\/hdi.12553","article-title":"Oral iron supplementation: Potential implications for the gut microbiome and metabolome in patients with CKD","volume":"21","author":"Kortman","year":"2017","journal-title":"Hemodial. Int."},{"key":"ref_40","first-page":"9","article-title":"Gut microbiota in chronic kidney disease","volume":"37","year":"2017","journal-title":"Nefrologia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000433564","article-title":"Target hemoglobin may be achieved with intravenous iron alone in anemic patients with cardiorenal syndrome: An observational study","volume":"5","author":"Shacham","year":"2015","journal-title":"Cardiorenal Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ki.2015.203","article-title":"Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients","volume":"88","author":"Gupta","year":"2015","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/ndt\/gfv277","article-title":"Ferric pyrophosphate citrate (Triferic\u2122) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients","volume":"30","author":"Fishbane","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"On behalf of the FIND-CKD Study Investigators FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/archinternmed.2011.445","article-title":"Dietary supplements and mortality rate in older women: The Iowa Women\u2019s Health Study","volume":"171","author":"Mursu","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e0132006","DOI":"10.1371\/journal.pone.0132006","article-title":"Reassessment of iron marker for prediction of dialysis iron overload: An MRI study","volume":"10","author":"Rostoker","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.clinbiochem.2008.07.007","article-title":"Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: A pilot study","volume":"41","author":"Anraku","year":"2008","journal-title":"Clin. Biochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12288-019-01170-1","article-title":"Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach","volume":"36","author":"Moradi","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1681\/ASN.2018101007","article-title":"Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis","volume":"30","author":"Sakaguchi","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ehj.2003.11.017","article-title":"Erytropoietin in cardiovascular diseases","volume":"25","author":"Voors","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/eurheartj\/ehn205","article-title":"Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients","volume":"29","author":"Lok","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jchf.2017.08.023","article-title":"Anemia in Heart Failure: Still Relevant?","volume":"6","author":"Beverborg","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin","volume":"38","author":"Hanna","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Del Vecchio, L., and Minutolo, R. (2021). ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040839"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000516901","article-title":"Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents","volume":"52","author":"Weir","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1388-9842(02)00115-0","article-title":"The importance of anemia and its correction in the management of severe congestive heart failure","volume":"4","author":"Silverberg","year":"2002","journal-title":"Eur. J. Heart Fail."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1523-1755.2005.00458.x","article-title":"Spanish Group for the study of the anemia and left ventricular hypertrophy in pre-dialysis patients. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin < 10 g\/dL","volume":"68","author":"Ayus","year":"2005","journal-title":"Kidney Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jjcc.2013.04.008","article-title":"KRN321 Study Group. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease","volume":"62","author":"Akaishi","year":"2013","journal-title":"J. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000190270","article-title":"Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic Patients","volume":"77","author":"Kuriyam","year":"1997","journal-title":"Nephron"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1523-1755.2004.00797.x","article-title":"Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial","volume":"66","author":"Gouva","year":"2004","journal-title":"Kidney Int."},{"key":"ref_63","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl., 3, 1\u2013150."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease","volume":"37","author":"McCullough","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e011130","DOI":"10.1161\/JAHA.118.011130","article-title":"Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients with Chronic Heart Failure and Chronic Kidney Disease","volume":"8","author":"Eisenga","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/ijpp.12133","article-title":"Predictors of erythropoietin use in patients with cardiorenal anaemia syndrome","volume":"23","author":"Jackevicius","year":"2014","journal-title":"Int. J. Pharm. Pract."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1056\/NEJMra1011165","article-title":"Oxygen sensing, homeostasis, and disease","volume":"365","author":"Semenza","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"HIF-PH inhibitors for anemia of CKD","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int. Suppl."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1744-9987.13820","article-title":"Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence","volume":"26","author":"Fujikawa","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","article-title":"Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus","volume":"304","author":"Vallon","year":"2013","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for the tubular Na+-H+-exchanger NHE3 in the natri-uretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.molmed.2018.10.006","article-title":"Inflflammation and hypoxia: HIF and PHD isoform selectivity","volume":"25","author":"Watts","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1002\/ehf2.14109","article-title":"Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study","volume":"9","author":"Iso","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience","volume":"26","author":"Sanghani","year":"2019","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/wrr.12708","article-title":"Roxadustat promotes angiogenesis through HIF-1\u03b1\/VEGF\/VEGFR2 signaling and accelerates cutaneous wound healing in diabetic rats","volume":"27","author":"Zhu","year":"2019","journal-title":"Wound Repair Regen."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_81","first-page":"354","article-title":"Roxadustat: Do we know all the answers?","volume":"23","author":"Li","year":"2023","journal-title":"Biomol. Biomed."},{"key":"ref_82","unstructured":"PMDA (2020, July 22). Japanese Pharmaceutical and Medical Devices Agency Report on Roxadustat. Available online: https:\/\/www.pmda.go.jp\/files\/000234811."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/1744-9987.12962","article-title":"A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients","volume":"24","author":"Tsubakihara","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000499111","article-title":"Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies","volume":"49","author":"Akizawa","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Crugliano, G., Serra, R., Ielapi, N., Battaglia, Y., Coppolino, G., Bolignano, D., Bracale, U.M., Pisani, A., Faga, T., and Michael, A. (2021). Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: \u201cCan the Promise Be Kept?\u201d. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212590"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s40265-022-01744-w","article-title":"Desidustat: First Approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","article-title":"Hypoxia-inducible factor-1\u03b1 is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy","volume":"9","author":"Bessho","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrneph.2015.193","article-title":"HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond","volume":"12","author":"Maxwell","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2005-07-2854","article-title":"Hepcidin inhibits in vitroerythroid colony formation at reduced erythropoietin concentrations","volume":"107","author":"Dallalio","year":"2006","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/fca.10.97","article-title":"Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio-renal anemia syndrome","volume":"6","author":"Kato","year":"2010","journal-title":"Future Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3389\/fphys.2019.01294","article-title":"Hepcidin and Anemia: A Tight Relationship","volume":"10","author":"Pagani","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/ki.2010.217","article-title":"Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure","volume":"78","author":"Srai","year":"2010","journal-title":"Kidney Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1111\/j.1755-5922.2010.00240.x","article-title":"Erythropoiesis-Stimulating Agents and Heart Failure","volume":"29","author":"Lipsic","year":"2011","journal-title":"Cardiovasc. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4078\/jrd.2016.23.1.37","article-title":"Clinical and Hematological Effects of Tocilizumab on Serum Hepcidin, Anemia Response and Disease Activity in Patients with Active Rheumatoid Arthritis","volume":"23","author":"Park","year":"2016","journal-title":"J. Rheum. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bcp.13877","article-title":"Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease","volume":"85","author":"Sheetz","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e0212023","DOI":"10.1371\/journal.pone.0212023","article-title":"First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis","volume":"14","author":"Renders","year":"2019","journal-title":"PLoS ONE"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/6\/1311\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:47:08Z","timestamp":1760125628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/6\/1311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":97,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["life13061311"],"URL":"https:\/\/doi.org\/10.3390\/life13061311","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}